Form D · Pharmaceuticals

InCarda Therapeutics, Inc.

Newark, CA · CIK 0001552622

Offering snapshot reported Oct 21, 2020 · SEC filing

Reported sold
$28M
Offering amount: $50M
Investors reported
5
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 6, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 21, 2020Initial$27,993,423No comparison5SEC filing
Nov 8, 2019Initial$35,296,018No comparison24SEC filing
May 2, 2017Initial$2,135,000No comparison16SEC filing
Dec 19, 2014Amendment$566,977$411,123vs Sep 11, 201313SEC filing
Sep 11, 2013Initial$155,854No comparison6SEC filing
Oct 17, 2012Initial$310,000No comparison5SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-378475

Source: Form D, filed Oct 21, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Isaac Cheng Director
Johan Christenson Director
Grace Colon Director, Executive
Alan Colowick Director
Andrew El Bardissi Director
Rangachari Narasimhan Director, Executive
Bischofberger Norbert Director
John S. Patton Director, Executive
Mc Carthy Reenie Director
Miller Samantha Executive
Carlos A. Schuler Director, Executive
Dan Welch Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
39899 Balentine Drive, Suite 185
Newark, CA, 94560